HK Stock Market Move | ND PAPER (02689) rose over 4% recently after announcing a new round of price adjustments, as downstream demand for inventory is expected to increase.
Nine Dragons Paper Holdings Limited (02689) rose over 4%. As of the time of reporting, it increased by 4.06%, priced at HKD 7.94, with a trading volume of HKD 93,696,800.
ND PAPER (02689) rose over 4%, currently up 4.06% at HKD 7.94, with a trading volume of HKD 93.6968 million.
In terms of news, several large paper companies have recently released price increase plans, leading to another wave of price hikes for various types of paper products. On July 29, ND PAPER's three major bases issued a price increase notice, with Dongguan Jiu Long and Taicang Jiu Long announcing price hikes for corrugated paper, recycled cardboard, premium kraft paper, and kraft paper; Beihai Jiu Long announced an increase in the premium V kraft price, with a price rise of 50 RMB/ton.
Huafu Securities believes that with August approaching, and major consumer events such as Mid-Autumn Festival, National Day, and e-commerce promotions coming soon, the downstream stocking demand will continue to intensify, providing some demand support for paper price increases. Bohai Securities maintains the judgment that rising paper prices will drive improvements in paper companies' performance, and is optimistic about the marginal profitability of packaging paper-related companies in the second quarter of this year.
Related Articles

Jiangxi Synergy Pharmaceutical (300636.SZ): Mirabegron and Empagliflozin have obtained GMP compliance certificates from the Australian Medicines and Therapeutics Administration.

CSC DEVELOPMENT (00830) expects that the profit attributable to shareholders in the first half of the year will decrease to approximately HKD 133 million compared to the same period last year.

The small molecule anticancer therapy developer BlossomHill (BLSM.US) has set an IPO price of $15 to $17 per share, aiming to raise $125 million.
Jiangxi Synergy Pharmaceutical (300636.SZ): Mirabegron and Empagliflozin have obtained GMP compliance certificates from the Australian Medicines and Therapeutics Administration.

CSC DEVELOPMENT (00830) expects that the profit attributable to shareholders in the first half of the year will decrease to approximately HKD 133 million compared to the same period last year.

The small molecule anticancer therapy developer BlossomHill (BLSM.US) has set an IPO price of $15 to $17 per share, aiming to raise $125 million.

RECOMMEND





